Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data: Difference between revisions
Jump to navigation
Jump to search
(→Who) |
|||
Line 5: | Line 5: | ||
==Amgen== | ==Amgen== | ||
===Who=== | ===Who=== | ||
* 14,000 employees | |||
===What=== | ===What=== | ||
* ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | * ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline |
Revision as of 21:36, 6 April 2009
NIH
Celera
Amgen
Who
- 14,000 employees
What
- ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
Where
News
Commons-Based, Peer-Production, and Open Access News
- Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
Genentech
Genzyme
Gilead Sciences
Biogen Idec
Cephalon
MedImmune
Celgene
Abraxis BioScience
ImClone Systems
IP Profile of Biggest for-profit companies in BGP